Emission computed tomographic methods for the in vivo quantification of radioligand-binding sites in human brain have previously been limited either by a lack of correction for possible effects of altered ligand transport or by highly complicated physiological models that preclude display of binding data in a detailed anatomical format. We investigated the application of a simplified compartmental model to the kinetic analysis of in vivo ligand binding to central benzodiazepine receptors. The human brain distribution of ["C]flumazenil, a s determined by dynamic positron emission tomography, combined with metabolite-corrected arterial blood samples, permitted estimations of local cerebral ligand transport and of receptor binding. This approach allows calculation of transport and binding "maps" on a pixel-by-pixel basis, resulting in the display of binding data in a familiar tomographic format while maintaining much of the physiological accuracy inherent in more complex methods. The results obtained in a study of 6 normal volunteers revealed good interindividual precision, with coefficients of variation between 10 and 155% of mean regional values, suggesting the utility of this approach in future clinical studies of benzodiazepine receptor binding. Of the available agents, we have focused our attention on FMZ for a variety of reasons. First, it appears to have a high relative proportion of "specific" (i.e., receptor-mediated) retention in the brain 11 1-141. Second, it is an antagonist of the BZR [lS, 161 and is devoid of significant physiological or pharmacologcal effects in normal individuals E171. Additionally, as an antagonist in in vitro assays, it demonstrates no alteration in its binding on the basis of endogenous or added GABA or barbiturates {G, 161. Finally, the binding of FMZ is specific for the central BZRs (the w1 and w2 subtypes) without significant affinity for the pe-
Emission computed tomographic methods for the in vivo quantification of radioligand-binding sites in human brain have previously been limited either by a lack of correction for possible effects of altered ligand transport or by highly complicated physiological models that preclude display of binding data in a detailed anatomical format. We investigated the application of a simplified compartmental model to the kinetic analysis of in vivo ligand binding to central benzodiazepine receptors. The human brain distribution of ["C]flumazenil, a s determined by dynamic positron emission tomography, combined with metabolite-corrected arterial blood samples, permitted estimations of local cerebral ligand transport and of receptor binding. This approach allows calculation of transport and binding "maps" on a pixel-by-pixel basis, resulting in the display of binding data in a familiar tomographic format while maintaining much of the physiological accuracy inherent in more complex methods. The results obtained in a study of 6 normal volunteers revealed good interindividual precision, with coefficients of variation between 10 and 155% of mean regional values, suggesting the utility of this approach in future clinical studies of benzodiazepine receptor binding. Of the available agents, we have focused our attention on FMZ for a variety of reasons. First, it appears to have a high relative proportion of "specific" (i.e., receptor-mediated) retention in the brain 11 1-141 19, 201 . In general, the approach to interpretation of these studies has centered o n the observation that the amounts and regional patterns of cerebral tracer retention are substantially altered by prior administration of competing bentodiazepines or by reducing the specific activity of t h e injected radiotracer. A formulation for analysis of ["C]FMZ distribution based on the assumption of pseudoequilibrium between blood and brain was presented previously r141. In our laboratory, we investigated the kinetics of cerebral E1'C)FMZ uptake and retention, and analyzed t h e results o n the basis of formal compartmental modeling 1213. In the present report, we describe the general imaging methods employed in our laboratory for {"C}FMZ studies. I n addition, a novel analysis on the basis of a simplified compartmental model is presented. This approach yields graphic pixel-by-pixel depictions of two parameters related to FMZ kinetics: the blood-to-brain transport rate constant and the brain tracer distribution volume (DV) relative to arterial plasma. The latter parameter is shown to be a precise measure and is proportional to local BZR availability as reported in in vitro studies.
Materials and Methods

Synthesis of {llC}Flumazenil
Carbon1 1-labeled FMZ (EN-methyl-"C)FMZ) was prepared by a modification [22] of the method of MaziGre and associates 1233. Specific activities at the time of injection ranged from 300 to 1,000 Ci/mmol.
Flumazenil Metabolite Chromatography
A procedure for rapid chromatographic separation of authentic FMZ from labeled metabolites in arterial blood was developed by analogy to a prior method used in the analysis of ["C]scopolamine distribution 1241. It utilizes the rapid separation achievable by column chromatography, combined with stringent solvent elution conditions and correction for recovery on the basis of a tritiated internal standard.
In order to characterize the chromatographic behaviors of FMZ and its major radiolabeled metabolites, [N-methyl3HfFMZ (New England Nuclear, Boston, MA) was administered intravenously to a 200-g male Sprague-Dawley rat. Approximately 15 minutes after injection, the animal was killed and samples of arterial blood and plasma, liver, and brain were collected. The solid tissues were homogenized in 4 vol of 95% ethanol, while aliquots of plasma underwent deproteinitation by addition of 1 vol of ethanol. The ethanolic suspensions were centrifuged to pellet the precipitates for 1 minute in a microcentrifuge. Aliquots of the supernatants and of the original whole blood and plasma samples were assayed for radioactivity with the use of liquid scintillation spectroscopy both before and after drying at 60 to 70°C. Additional aliquots of the ethanolic supernatants were concentrated under vacuum and then chromatographed on silica thin-layer chromatography (TLC) plates (No. 5721, E. Merck, Darmstadt, Federal Republic of Germany) in each of two solvent systems: (1) hexane-benzene-dioxaneammonium hydroxide, 70:50:45:0.5; and (2) dichloromethane-methanol, 9: 1. Following development and drying, the plates were sprayed with a fluorographic enhancer (En3hance, New England Nuclear, Boston, MA) and apposed to x-ray film for 7 to 14 days at -70°C. The resulting autoradiograms were used to locate and recover major labeled metabolites from the plates.
Column chromatographic separation of C3H]FMZ from two major labeled metabolites was investigated with the use of Sep-Pak C,, cartridges (Waters, Milford, MA). The columns were prewashed with 0.1 ml of triethylamine followed by 10 ml of methanol and 10 ml of phosphate-buffered saline solution (PBS): sodium chloride (NaCI) 137 mM; potassium chloride (KC1) 3 mM; sodium phosphate (Na,HP04) 8 mM; potassium phosphate (KH,P04) 1.5 mM; p H 7.4. Samples of authentic C3H)FMZ or labeled metabolite fractions were added in 1-ml volumes of PBS. Columns were then washed with mobile phases of varying methanol-PBS content. Eluted fractions were collected and assayed by liquid scintillation spectroscopy
PET Data Acquisition
Six young volunteers were recruited by advertisement for participation in the study. They were free of significant current illness by history, had normal findings on general physical and neurological examinations, were not taking prescription or over-the-counter medications with central nervous system actions, were nonsmokers, and did not consume excessive amounts of alcohol or caffeine. informed consent was obtained prior to all studies, and the procedures were approved by the local institutional review boards governing the use of radionuclides and human subjects in research.
The PET imaging was performed with a CTI/Siemens 93 1/08-12 scanner (Siemens Gammasonics, Inc, Hoffman Estates, IL) in the stationary acquisition mode. The tomograph has a reconstructed spatial resolution of 6-to 7-mm full width at half maximum (FWHM) within planes and 7-to 8-mm FWHM in the axial direction. Data from eight rings are simultaneously acquired, permitting reconstruction of 15 planes, each separated by 6.75 mm.
Following establishment of percutaneous radial artery and venous access, subjects were positioned supine, with the eyes and ears unoccluded. The scanned field of view encompassed approximately 100 mm, beginning inferiorly at 1.0 cm above the orbitomeatal line. Five radioactive fiduciary markers, 1 to 2 mm in diameter, each labeled with approximately 8 LCi of "C, were affixed to the scalp within the field of view. A dynamic series of PET scans was initiated following bolus intravenous injection of 30 to 50 mCi of {"CIFMZ, containing less than 30 kg of ligand. Scans were acquired over the following 90 minutes according to the following protocol: 4 x 30 seconds; 3 x 1 minute; 2 x 2.5 minutes; 2 X 5 minutes; and 7 x 10 minutes.
Timed arterial blood samples were withdrawn into heparinized syringes every 10 seconds for the first 2 minutes, followed by additional discrete samples at progressively longer intervals throughout the remainder of the scanning session. Following centrifugation, plasma aliquots were assayed for total radioactivity with the use of a sodium iodide well-counter. Additional aliquots were processed by column chromatography at 1, 2, 3, 4 , 5, 7.5, 10, 15, 20, 30, 45, 60, and 90 minutes to quantify the unmetabolized ["CIFMZ fraction. These latter plasma samples of 0.4 ml were added to tubes containing 0.6 ml of PBS, which additionally contained approximately 0.05 pCi of C3H)FMZ to act as an internal standard for recovery. Following application to the Sep-Pak column, samples were washed with 9 ml of PBS-methanol, 6535. The unmetabolized fraction was then eluted from the column with 5 ml of methanol. The wash and FMZ fractions thus obtained were assayed for "C activity in the wellcounter. Aliquots were taken for assay of 3H by liquid scintillation spectroscopy following decay of "C. The unmetabolized fraction of [ "C)FMZ in the original plasma sample was then calculated as described elsewhere 1241. Total arterial plasma {"CIFMZ was used as the input function for compartmental analysis, since prior work demonstrated only slight plasma protein binding [25J The emission scans were reconstructed and realigned to a common spatial orientation on the basis of the scalp fiduciaries. The images were corrected for attenuation by calculation with the use of an ellipse, and were scaled to account for the differing scan acquisition times and for "C decay.
Prior receptor radioligand biodistribution experiments from our laboratory have been analyzed with the use of a compartmental model that distinguishes free, nonspecifically bound, and specifically bound tracer in tissue (Fig 1) [26}. Detailed analysis of the kinetic behavior of ["C}FMZ in human brain indicates that the tissue tracer pools are in rapid exchange, allowing simplification to a single tissue compartment representing the combined tracer pools [21] . In this case, the mathematical description of regional brain activity C+ versus time t is given by: where and where C,(t) is the tracer activity in arterial plasma; @ denotes the operation of convolution; f represents local cerebral blood flow; PS represents the capillary permeabilitysurface area product; and rate constants a, b, and K, through kd are as defined in the legend to Figure 1 . The PET data, omitting the first 30 seconds to minimize effects of intravascular activity, were fit to the relationship in Equation 1 on a pixel-by-pixel basis with the use of the metabolite-corrected arterial input curve and a weighted integral lookup table approach 127, 28). This allows calculation and display of two parametric maps, one reflecting ligand transport from blood to brain (KJ, the second depicting the local ligand DV. The DV is related to the model parameters and to regional receptor availability as follows: where k,, and kOfi are the kinetic rate constants for ligand receptor binding and dissociation, R is the available receptor concentration, and KD is the equilibrium binding affinity constant. In the case of a ligand with relatively high affinity for receptor-binding sites (low KD), and when there are large concentrations of receptors avadable for binding, the DV is dominated by k,/k, and is proportional to R.
Following calculation of parametric images of K, and DV, whole-brain and selected region-of-interest analyses were performed. Regions were identified according to the K1 images, as these afforded good brain structural delineation, even in regions with relatively low BZR binding. The regions were then mapped onto the corresponding tissue activity and parametric DV images. Average brain parameter estimates were accomplished by calculation of the weighted mean of all 15 whole-slice regions. Whole-brain uptake was then estimated by assumption of a brain volume of 1,237 ml for normal young adults [29] .
Results
Metabolic Fate of {'H)FLumazenil in the Rat
Following systemic injection, I3H]FMZ is rapidly metabolized. Comparison of total and nonvolatile activities revealed the presence of significant amounts of volatile metabolites, which account for over 955% of the activity in plasma and for 15 to 20% of the activity in brain and liver at 15 minutes after injection. Chromatographic analysis of nonvolatile activity (Fig 2) revealed the presence of two classes of labeled polar metabolites, one remaining at the origin (band I) and a second (band 11) migrating with an & approximately two thirds that of authentic FMZ. Unchanged FMZ accounted for over 995% of nonvolatile brain activity, but only 32% and 14% of that recovered from plasma and liver, respectively. In plasma, 63% of the nonvolatile activity was in band I and 6% was attributable to band 11.
Rapid Column Chromatography of Flumazenil in Plasma
Samples of both 'H-labeled metabolites and of C3H}FMZ were applied to Sep-Pak columns and eluted with mobiie phases containing PBS and between 0 and 45% methanol. The best differential retention of FMZ versus the metabolites was achieved with use of 35% methanol. In this case, washing of the column with 8 ml removed over 98% of the band I and 91% of the band I1 metabolite activities, while retaining 505% of the FMZ applied (Fig 3) . In the subsequent processing of arterial samples from human studies, a 9-ml wash volume was adopted to further ensure high purity of the FMZ fraction. Volume of Mobile Phase, ml In arterial plasma samples collected following injection in humans, authentic {"C}FMZ cleared rapidly from the circulation (Fig 4) . The presence of labeled metabolites was detectable within 2 to 3 minutes, and increased with time to account for approximately 7 5 5% of the activity by 90 minutes after injection.
Uptake and Distribution of {"C}Flumazenil in Human Brain
FMZ entered the brain readily, reaching peak levels in whole brain between 5 and 15 mintues after injection. 'Calculated on the basis of the injected activity and the weighted average of ["C]flumazenil activity within all scanned slices between 5 and 7.5 minutes after injection, assuming a whole-brain volume of 1,237 ml. bCalculated from the weighted average of [''Clflumazenil activity within all scanned slices between 5 and 7.5 minutes after iniection and the specific activity of the injected tracer.
The whole-brain uptake of ["CJFMZ between 5 and 7.5 minutes after injection was 9.3 2 3.5% (mean t standard deviation) of the ,injected dose, resulting in an average brain concentration of 6 * 4 nM ( Table 1) .
Analysis of regional time-activity curves indicated rapid ligand uptake across a wide variety of gray matter structures with differential retention according to the anticipated regional BZR density (Fig 5) . Thus, activity cleared most slowly from the cerebral cortex; at an intermediate rate from the basal ganglia, thalamus, and cerebellar cortex; and most rapidly from the pons.
Simplified Compartmental Analysis of Regional {"C}Flzlmazenil Distribution
Parametric images of FMZ transport (Fig 6) 10 and 14%. Further improvement in precision was achieved in most regions by representing the parameters as regional ratios to the whole-brain average for each study. In this case, COVs for K, and for DV ranged between 2 and 11%, with the exception of the pons, where no significant improvement was noted.
Discussion
The present study confirmed and extended prior findings indicating the utility of radiolabeled FMZ in the in vivo measurement of central BZR availability. In agreement with studies on the metabolism of pharmacological doses of FMZ [25, 321 and of tracer doses of ["CIFMZ [33] , we found evidence in both the rat and the human that FMZ is rapidly metabolized. However, chromatographic analysis of activity extracted from rat brain revealed that detectable levels of nonvolatile FMZ metabolites are excluded by the blood-brain barrier. Both of the radiolabeled FMZs employed in our studies were labeled in the same position (either 3H or "C in the N-methyl position), allowing extrapolation of the animal data to the human studies regarding the disposition of metabolites retaining the N-methyl group. In addition, a prior study following injection of the major "C-labeled FMZ metabolite, an acid FMZ derivative (R015-3890), revealed directly that there is no appreciable brain uptake in normal humans [343.
Thus, the cerebral time-activity curves obtained in normal human studies may be interpreted as representing authentic ["CIFMZ. The finding of significant relative amounts of volatile activity in the rat following injection of r3H)FMZ, however, suggests the need for caution in interpretation of total activity levels following its in vivo injection in experimental animals. The volatile activity in this instance is likely to reflect the presence of'[3H)water, produced during N-demethylation, by 'H exchange, or both. While labeled water would not be produced in the human studies with ["CIFMZ, ['lC}carbon dioxide might theoretically arise via N-demethylation and subsequent oxidation of the [ "Clformaldehyde. Although the cerebral time-activity curves in our human experiments do not suggest the presence of a labeled metabolite that enters the brain and accumulates at later times, as might be expected ,of {"C}carbon dioxide, it would be important to verify directly its absence in future clinical experiments. We present here a colunm chromatographic method for the rapid metabolite correction of arterial plasma samples in clinical ["C}FMZ imaging studies. The method is capable of handling over 15 to 20 samples from a single FMZ administration within the time constraints imposed by the 20-minute half-life of "C. Our results underscore the need for chromatographic processing of plasma to obtain the correct tracer input function required in tracer kinetic analysis. Significant metabolism of FMZ was detectable within minutes following intravenous injection, and the fraction of plasma activity attributable to unchanged FMZ fell to less than 30% within 15 minutes after injection. Future applications of ["C)FMZ in disease states must therefore be conservative in their design and interpretation. In cases of impaired blood-brain barrier function, some or all of the labeled FMZ metabolites might enter the brain, confounding interpretation of the PET data.
Thus, parallel PET examinations of blood-brain barrier integrity may be necessary in some instances.
The method of analysis presented here, resulting in parametric images of radioligand transport and of tissue DV, was applied previously in our laboratories to the imaging of muscarinic receptors [35] . An alternative method previously proposed for analysis of in vivo ["CIFMZ binding {14} makes the assumption that at later times following injection of tracer, an equilibrium between free tracer and specifically bound tracer is achieved. In order to rigorously apply this solution, a scan is required at a time when the nonspecific binding is minimal and unchanging and when total activity in the brain region of interest is constant. This may theoretically require scans at different times after injection for individual brain regions, due to local differences in transport and binding. An approximation of these conditions may be found for ligands that bind and dissociate rapidly from specific sites, by scanning late after injection as tracer is cleared from the brain. The similarity in regional patterns of the parametric DV and the 15-to 20-minute static activity images and the sub-sequent quahtitdtive regional comparisons from these images support this assumption. However, it has been demonstrated that the delayed tissue activity under these circumstances may actually overestimate regional receptor availability C36, 37) . This occurs when the relationship between specific binding and the free tissue ligand represents a secular rather than a true equilibrium, due to continuing decline in plasma tracer concentration. Under these conditions, the overestimate of binding is most severe when the rate of blood clearance is greater than clearance from the brain, and should be most evident in regions of fewest receptors. Thus, the pseudoequilibrium scans in the current study indicate greater apparent receptor binding in the thalamus, basal ganglia, and cerebellum (relative to the cerebral cortex) than do the estimates from the DV maps. Nevertheless, the simplicity of the pseudoequilibrium method may ultimately allow more widespread application of receptor imaging, and it is readily adaptable to SPECT imaging of iodonated ligands, where lower tracer activity doses are permissible and longer image acquisition times are necessary.
Our simplhed compartmental analysis appears promising for application to BZR measurements in clinical research. It is necessary, however, to validate further the pharmacological and physiological sensitivities and specificities of the procedure in normal volunteers and, perhaps, in patients with selected pathological conditions as well. Many of the potential applications of BZR imaging involve detection of receptor losses id neurodegenerative diseases including Huntington's disease {30, 381, olivopontocerebellar atrophy [393, and Alzheimer's disease [40] or in the study of focal epilepsy [41, 42} . In these cases, local cerebral metabolism and perfusion are reduced in discrete areas of bkaiii C43-461, and it may be predicted that ligand transport in receptor imaging studies will be comparably reduced. Thus, it becomes crucial to isolate effects Of ligand transport from measurement of receptor binding in the analysis of local cerebral ligand concentration. The simplified two-parameter method presented ih the current study may prove invaluable in these settings, permitting simultaneous estimation of transport alterations in addition to receptor measurements. We have subsequently found that a shortened imaging period of 60 minutes following administration of 20 to 25 mCi of E1'C}FMZ results in parametric images of high quality. Test-retest experiments performed recently in our laboratory with this method demonstrated that augmentation of cerebral blood flow to the ocdpital cortex during visual stimulation results in increased FMZ transport, while FMZ binding estimates are unchanged {47}.
The ihitial studies reported here reveal an unexpectedly low variability in both the ligand transport and the DV measures. Within-individual reliability is sugested by the apparent favorable signal-to-noise ratios of the parametric images, since cerebral structure is readily identifiable in both parametric maps. Calculation of the parametric images makes use of all of the information recorded during the scanning session, and in the case of FMZ, results in images that appear favorable by comparison to the statistical quahty of single delayed images. The low between-individual coefficients of variation observed suggest that it should be feasible to detect anticipated pathological receptor changes in the conditions listed previously, using modest numbers of patients. Thus, receptor changes of 20% would be detectable at the fi < 0.05 level with 0.8 power, using experimental groups of 10 subjects. Actually, the precision of the method appears to equal or exceed those of the most frequently employed PET measures of metabolism or blood flow.
A final advantage of the pixel-by-pixel fits to the two-parameter, two-compartment model employed here is in the utility of the h a g e s themselves. The pixel-by-pixel depictions of ligand transport and binding from the present method permit visual screening of ligand transport and binding in the entire brain. Unanticipated local changes may thus be detected without the need for time and labor-intensive data analyses needed by more complex tracer compartmental models. The detailed kinetic descriptions of both blood and brain activity collected, however, will permit post hoc application of these more complex analyses when indicated.
In summary, we developed a simplified compartmental model and analysis of {"C}FMZ distribution in the human brain, which results in images of AZR binding. Although the method requires the sampling and processing of arterial blood samples in addition to collection of PET data, it results in precise transport and binding parameter estimates.
